CVRx Share Price Today

Rosen Law joins CVRx class action over sales practices

Rosen Law Firm filed a class action complaint against CVRx on November 12, 2026. Allegations include improper marketing of Barostim and kickbacks violating False Claims Act. Investors who bought shares between July 25, 2023, and August 6, 2026, are eligible. Lead plaintiff motion deadline is January 8, 2027. Stock price fell 59.76% following disclosure of DOJ investigation and guidance cut.

Lake Street lowers CVRx price target to $1.5, maintains Hold

Lake Street maintains a Hold rating on CVRx. Price target lowered from $3.5 to $1.5. Analyst Frank Takkinen issued the revision.

William Blair downgrades CVRx to Market Perform

William Blair analyst Brandon Vazquez downgraded CVRx to Market Perform. Previous rating was Outperform. No financial figures or price targets were disclosed with the downgrade.

CVRx Q2FY26 Results: Revenue up 16%, full-year guidance lowered

Revenue rose 16% YoY to $15.7 million in Q2FY26. Full-year revenue guidance lowered to $58-$60 million range. Net loss narrowed to $14.0 million from $14.7 million YoY. Salesforce productivity issues in high-turnover regions cited as primary driver for guidance cut.

Hagens Berman probes CVRx Inc. for securities fraud after 59% stock drop

Hagens Berman opened an investigation into CVRx Inc. following a 59% stock drop on August 7, 2026. The probe follows a DOJ Civil Investigative Demand received May 14, 2026, regarding potential false claims. CVRx cut 2026 revenue guidance citing sales force turnover and flat growth in territories. Primary Medicare Advantage payer approvals fell from 80% to 25%, impacting reimbursement rates. Chief Revenue Officer Robert John was terminated abruptly on August 10, 2026.

CVRx's Barostim to feature in eight events at HFSA 2026 meeting

Barostim will be featured across eight events at the HFSA Annual Scientific Meeting 2026, held October 9-12 in Phoenix. New analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, will be presented by Dr. Dmitry Yaranov in a Sunday plenary session. First real-world evidence of reduced hospitalization burden in HFmrEF patients will be presented by Dr. Javed Butler in a rapid-fire session. BENEFIT-HF, a landmark clinical trial evaluating Barostim in an expanded population, will be included in the clinical trial ePoster hub. CVRx will host two sponsored symposia on October 9 and October 11 covering clinical evidence, patient selection, and program development for Barostim.